Sicard v. Secretary of Health and Human Services

United States Court of Federal Claims·Decided December 2, 2019·No. 16-332·Unpublished

Opinion

In the United States Court of Federal Claims OFFICE OF SPECIAL MASTERS No. 16-332V Filed: November 4, 2019

* * * * * * * * * * * * * * * SEAN SICARD, * UNPUBLISHED * Petitioner, * v. * Decision on Interim Attorneys’ Fees and * Costs; Expert Costs SECRETARY OF HEALTH * AND HUMAN SERVICES, * * Respondent. * * * * * * * * * * * * * * * *

Andrew Downing, Esq., Van Cott & Talamante, PLLC, Phoenix, AZ, for petitioner. Daniel Principato, Esq., U.S. Department of Justice, Washington, DC, for respondent.

DECISION ON INTERIM ATTORNEYS’ FEES AND COSTS1

Roth, Special Master:

On March 15, 2016, Dorothy Sicard filed a petition for compensation under the National Vaccine Injury Compensation Program2 on behalf of her minor child, S.S. Sean Sicard (“Mr. Sicard” or “petitioner”) was substituted in as petitioner on June 12, 2018, after reaching the age of majority. See ECF No. 57. Petitioner alleges that he developed antiphospholipid antibody syndrome (“APS”) and/or systemic lupus erythematosus (“SLE”) as a result of receiving his third human papillomavirus (“HPV”) vaccination on March 15, 2013. Petition (“Pet.”), ECF No. 1.

1 Although this Decision has been formally designated “unpublished,” it will nevertheless be posted on the Court of Federal Claims’s website, in accordance with the E-Government Act of 2002, Pub. L. No. 107- 347, 116 Stat. 2899, 2913 (codified as amended at 44 U.S.C. § 3501 note (2006)). This means the Decision will be available to anyone with access to the internet. However, the parties may object to the Decision’s inclusion of certain kinds of confidential information. Specifically, under Vaccine Rule 18(b), each party has fourteen days within which to request redaction “of any information furnished by that party: (1) that is a trade secret or commercial or financial in substance and is privileged or confidential; or (2) that includes medical files or similar files, the disclosure of which would constitute a clearly unwarranted invasion of privacy.” Vaccine Rule 18(b). Otherwise, the whole Decision will be available to the public. Id.

2 National Childhood Vaccine Injury Act of 1986, Pub. L. No. 99-660, 100 Stat. 3755. Hereinafter, for ease of citation, all “§” references to the Vaccine Act will be to the pertinent subparagraph of 42 U.S.C. § 300aa (2012). I. Procedural History

The petition was filed on March 15, 2016. ECF No. 1. On April 8, 2016, petitioner filed medical records as Petitioner’s Exhibits (“Pet. Ex.”) 1-8. ECF No. 7. Petitioner filed a Statement of Completion on April 12, 2016. ECF No. 8.

Respondent filed his Rule 4(c) Report on October 25, 2016, recommending against compensation in this matter. ECF No. 18.

Petitioner filed additional medical records on November 8, 2016, and an expert report from an immunologist, Dr. Yehuda Shoenfeld, on January 17, 2017. Pet. Ex. 10-12, ECF No. 20; Pet. Ex. 13-14, ECF No. 23. Petitioner filed supporting medical literature through February and March of 2017. See ECF Nos. 28, 30-33.

Respondent filed expert reports from Dr. Lindsay Whitton, an immunologist, and Dr. Carlos Rose, a rheumatologist, and supporting medical literature on May 8, 2017. Resp. Ex. A, Tabs 1-9, ECF No. 34; Resp. Ex. A, Tabs 10-16, ECF No. 35; Resp. Ex. B, Tabs 1-9, ECF No. 36; Resp. Ex. B, Tabs 10-11, ECF No. 37; Resp. Ex. C-D, ECF No. 38.

Petitioner filed supplemental expert reports from Dr. Shoenfeld on October 4, 2017 and October 23, 2017. Pet. Ex. 49, ECF No. 40; Pet. Ex. 50, ECF No. 42. Petitioner filed supporting literature for these reports in March of 2018. See ECF Nos. 45-48, 50.

Respondent filed responsive expert reports from Dr. Whitton and Dr. Rose and supporting medical literature on April 19, 2018. Resp. Ex. E, Tabs 1-9, ECF No. 51; Resp. Ex. E, Tabs 10- 14, ECF No. 52; Resp. Ex. F, Tabs 1-2, ECF No. 53; Resp. Ex. G, ECF No. 54.

During a status conference on June 12, 2018, petitioner’s counsel advised that petitioner intended to continue with a different expert and requested the opportunity to file an expert report from a rheumatologist. Scheduling Order at 1, ECF No. 56. Petitioner filed an expert report from Dr. Thomas Zizic, a rheumatologist, on October 10, 2018. Pet. Ex. 92, ECF No. 59. On March 11, 2019, respondent filed expert reports from Dr. Whitton and Dr. Rose responding to Dr. Zizic. Resp. Ex. H, Tabs 1-9, ECF No. 62; Resp. Ex. H, Tabs 10-13; Resp. Ex. I, Tabs 1-3, ECF No. 64.

On May 14, 2019, petitioner filed Dr. Zizic’s CV along with a Motion to Limit Dr. Whitton’s testimony. Pet. Ex. 94, ECF No. 67; Motion to Limit, ECF No. 68. Respondent filed a response to petitioner’s motion on May 22, 2019. ECF No. 70.

A status conference was held on May 23, 2019. Petitioner was ordered to file a supplemental expert report from Dr. Zizic. Scheduling Order at 2-3, ECF No. 71. Petitioner’s Motion to Limit was denied. Id. at 3.

On October 10, 2019, petitioner filed a Motion for Interim Attorneys’ Fees and Costs. Mot. Interim Fees, ECF No. 75. Petitioner requests attorneys’ fees in the amount of $35,023.50, and attorneys’ costs in the amount of $58,181.12, for a total amount of $93,204.62. Id. at 6. In

2 accordance with General Order #9, petitioner’s counsel represents that petitioner did not incur any out-of-pocket expenses. Id. at 1.

On October 24, 2019, respondent filed a response to petitioner’s Motion for Interim Fees. Response, ECF No. 77. Respondent stated that he was “satisfied the statutory requirements for n aware of attorneys’ fees and costs are met in this case.” Id. at 2. However, he noted that Dr. Zizic billed 105 hours for a total of $42,040.00 in fees for drafting a single expert report, and petitioner’s counsel recently submitted an invoice from Dr. Zizic in another matter which also charged $40,000.00 for a single expert report. Id. at 1. Respondent did not specifically object to Dr. Zizic’s bill, but stated, “It is important to evaluate the reasonableness of the requested litigation costs, as petitioners are not given a ‘blank check to incur expenses’ to be paid by the Vaccine Trust Fund.” Id. at 3 n.2 (internal citations omitted). Ultimately, respondent “respectfully recommend[ed] that the Special Master exercise her discretion and determine a reasonable award for attorneys’ fees and costs.” Id. at 3.

Petitioner did not file a reply. This matter is now ripe for decision.

II. Legal Framework

The Vaccine Act permits an award of “reasonable attorneys’ fees” and “other costs.” § 15(e)(1). If a petitioner succeeds on the merits of his or her claim, he or she is entitled to an award of reasonable attorneys’ fees and costs. Id.; see Sebelius v. Cloer, 133 S. Ct. 1886, 1891 (2013). However, a petitioner need not prevail on entitlement to receive a fee award as long as the petition was brought in “good faith” and there was a “reasonable basis” for the claim to proceed. § 15(e)(1).

The Federal Circuit has endorsed the use of the lodestar approach to determine what constitutes “reasonable attorneys’ fees” and “other costs” under the Vaccine Act. Avera v. Sec’y of Health & Human Servs., 515 F.3d 1343, 1349 (Fed. Cir. 2008). Under this approach, “an initial estimate of a reasonable attorneys’ fee” is calculated by “multiplying the number of hours reasonably expended on the litigation times a reasonable hourly rate.” Id. at 1347-48 (quoting Blum v. Stenson, 465 U.S. 886, 888 (1984)).

Free access — add to your briefcase to read the full text and ask questions with AI

Sicard v. Secretary of Health and Human Services, (uscfc 2019).

Sicard v. Secretary of Health and Human Services (Sicard v. Secretary of Health and Human Services) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related